News

The company has received an initial investment of $10 million, with an additional $15 million due upon the achievement of certain milestones. Proceeds from the Series B financing

The study was intended to see if a combination of ganetespib and docetaxel would work better than docetaxel alone for advanced non-small cell lung adenocarcinoma. Synta halted the

China-based Yabao will co-develop Lilly’s sodium-glucose linked transporter inhibitor (SGLT1) molecule. Under the deal, Yabao secures the rights to develop and commercialize the SGLT1 compound in China, while

SV Life Sciences will manage the Dementia Discovery Fund (DDF), whose investors include the government’s Department of Health (DoH), Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly,

It will join targeted Pulse Electro Magnetic Field therapy (tPEMF) and closed-loop Transcranial Electrical Stimulation (cl-TES) as one of Rio Grande Neurosciences’ core technologies. Despite undergoing treatment with

The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials. Science 37 co-founder

The partnership will seek to apply Riverside Research’s patented, quantitative, tissue-characterization algorithms to the ExactVu™ high-resolution micro-ultrasound platform to develop new capabilities in the system’s ability to detect

The summit aims to address the vital role of scientific research in the improvement and sustainable development of the African population health, with specific emphasis on how to

The facility, which is expected to start operations in 2017, will manufacture about 40 million packs and 850 million tablets of around 30 medicines every year. It represents